WuXi Biologics (Cayman) マネジメント
マネジメント 基準チェック /24
WuXi Biologics (Cayman)の CEO はChris Chenで、 Jan2016年に任命され、 の在任期間は 8.83年です。 の年間総報酬はCN¥ 96.91Mで、 4.1%給与と95.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.35%を直接所有しており、その価値はHK$ 207.15M 。経営陣と取締役会の平均在任期間はそれぞれ2.6年と7.2年です。
主要情報
Chris Chen
最高経営責任者
CN¥96.9m
報酬総額
| CEO給与比率 | 4.1% |
| CEO在任期間 | 8.8yrs |
| CEOの所有権 | 0.4% |
| 経営陣の平均在職期間 | 2.6yrs |
| 取締役会の平均在任期間 | 7.2yrs |
経営陣の近況
Recent updates
After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar
Sep 26
WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet
Sep 12Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why
Jun 12Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%
Jun 11Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding
Jun 11Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge
Mar 04Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade
Dec 08Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Nov 10What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
Sep 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate
Aug 10Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?
Jun 19Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
May 12Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?
Mar 13Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?
Feb 13An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued
Jan 30Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching
Nov 20With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case
Nov 08Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?
Oct 27WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?
Aug 15CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥3b |
| Mar 31 2024 | n/a | n/a | CN¥3b |
| Dec 31 2023 | CN¥97m | CN¥4m | CN¥3b |
| Sep 30 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥4b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥79m | CN¥3m | CN¥4b |
| Sep 30 2022 | n/a | n/a | CN¥4b |
| Jun 30 2022 | n/a | n/a | CN¥4b |
| Mar 31 2022 | n/a | n/a | CN¥4b |
| Dec 31 2021 | CN¥51m | CN¥3m | CN¥3b |
| Sep 30 2021 | n/a | n/a | CN¥3b |
| Jun 30 2021 | n/a | n/a | CN¥3b |
| Mar 31 2021 | n/a | n/a | CN¥2b |
| Dec 31 2020 | CN¥31m | CN¥3m | CN¥2b |
| Sep 30 2020 | n/a | n/a | CN¥1b |
| Jun 30 2020 | n/a | n/a | CN¥1b |
| Mar 31 2020 | n/a | n/a | CN¥1b |
| Dec 31 2019 | CN¥25m | CN¥3m | CN¥1b |
| Sep 30 2019 | n/a | n/a | CN¥922m |
| Jun 30 2019 | n/a | n/a | CN¥831m |
| Mar 31 2019 | n/a | n/a | CN¥731m |
| Dec 31 2018 | CN¥20m | CN¥2m | CN¥631m |
| Sep 30 2018 | n/a | n/a | CN¥520m |
| Jun 30 2018 | n/a | n/a | CN¥410m |
| Mar 31 2018 | n/a | n/a | CN¥331m |
| Dec 31 2017 | CN¥24m | CN¥2m | CN¥253m |
報酬と市場: Chrisの 総報酬 ($USD 13.35M ) は、 Hong Kong市場 ($USD 868.11K ) の同規模の企業の平均を上回っています。
報酬と収益: Chrisの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。
CEO（最高経営責任者
Chris Chen (51 yo)
8.8yrs
在職期間
CN¥96,911,000
報酬
Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder & Chairman | 10.8yrs | データなし | データなし | |
| CEO & Executive Director | 8.8yrs | CN¥96.91m | 0.35% HK$ 207.2m | |
| Honorary President of Global Biologics Development | 9.6yrs | CN¥32.89m | 0.013% HK$ 7.9m | |
| CFO & Executive VP | 3yrs | データなし | データなし | |
| COO & Senior VP | less than a year | データなし | データなし | |
| Chief Technology Officer and Executive VP of Global Biologics Development Department | less than a year | データなし | データなし | |
| Chief Scientific Officer & President of Global Biologics Research | no data | データなし | データなし | |
| Senior VP & Head of Investor Relations | less than a year | データなし | データなし | |
| Chief Compliance Officer | 2.2yrs | データなし | データなし | |
| VP & Head of Global Human Resources | no data | データなし | データなし | |
| Senior VP and Head of Global BD & Alliance Management | no data | データなし | データなし | |
| Chief Digital Officer | 4.8yrs | データなし | データなし |
2.6yrs
平均在職期間
56.5yo
平均年齢
経験豊富な経営陣: 2269の経営陣は 経験豊富 であると考えられます ( 2.6年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder & Chairman | 10.8yrs | データなし | データなし | |
| CEO & Executive Director | 10.8yrs | CN¥96.91m | 0.35% HK$ 207.2m | |
| Honorary President of Global Biologics Development | 8.5yrs | CN¥32.89m | 0.013% HK$ 7.9m | |
| Independent Non-Executive Director | 1.5yrs | CN¥710.00k | 0.00063% HK$ 369.8k | |
| Member of Scientific Advisory Board | 6.8yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 6.8yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 6.8yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 6.8yrs | データなし | データなし | |
| Independent Non-Executive Director | 7.5yrs | CN¥906.00k | 0.00053% HK$ 311.1k | |
| Non-Executive Director | 8.5yrs | データなし | データなし | |
| Non-Executive Director | 8.5yrs | データなし | データなし | |
| Independent Non-Executive Director | 4.4yrs | CN¥933.00k | 0.0050% HK$ 2.9m |
7.2yrs
平均在職期間
59.5yo
平均年齢
経験豊富なボード: 2269の 取締役会 は 経験豊富 であると考えられます ( 7.2年の平均在任期間)。